[1] |
Mohan M, Buros A, Mathur P, et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease [J]. Am J Hematol, 2017, 92(8): 739-745.
|
[2] |
Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström′s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2018, 29(Suppl 4): iv41-iv50.
|
[3] |
童玲,成水芹,陈光,等. 华氏巨球蛋白血症相关肾损害的临床病理特征[J]. 肾脏病与透析肾移植杂志,2020, 29(3): 226-231.
|
[4] |
Uppal NN, Monga D, Vernace MA, et al. Kidney diseases associated with Waldenström macroglobulinemia [J]. Nephrol Dial Transplant, 2019, 34(10): 1644-1652.
|
[5] |
王海燕. 肾脏病学(第3版)[M]. 北京:人民卫生出版社. 2008, 1494-1500.
|
[6] |
Vos JM, Gustine J, Rennke HG, et al. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes [J]. Br J Haematol, 2016, 175(4): 623-630.
|
[7] |
Chauvet S, Bridoux F, Ecotière L, et al. Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients [J]. Am J Kidney Dis, 2015, 66(5): 756-767.
|
[8] |
冯均才,李有华. 以肾病综合征为首发表现的华氏巨球蛋白血症一例[J].中华老年医学杂志,1999, 8(2): 87.
|
[9] |
牛挺. 华氏巨球蛋白血症/淋巴浆细胞淋巴瘤NCCN新版指南(2018.V1)解读[J]. 华西医学,2018, 33(4): 393-397.
|
[10] |
Xu L, Tsakmaklis N, Yang G, et al. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia [J]. Blood, 2017, 129(18): 2519-2525.
|